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ABSTRACT
Objective: The objective of this selective EBM review is to determine, “Do probiotics decrease
depressive symptoms in patients with low mood?”
Study Design: A systematic review of three double blind, randomized control trials (RCTs)
published between 2016 and 2019.
Data Sources: All three RCTs were found using PubMed and published in English in peerreviewed journals. The articles were chosen based on their attention to patient-oriented evidence
that matters (POEMS) and their relevance to the clinical question.
Outcome Measured: All three articles utilized either the Beck Depression Index (BDI) and/or
the Depression Anxiety Stress Scale (DASS) to measure the severity of depressive symptoms.
The higher the score, the more severe the level of depression. The between group difference, Fscore, or mean change from baseline were calculated from scores recorded before and after
intervention.
Results: The decrease in depressive symptoms of the placebo group compared the probiotic
group were found significant in one out of the three RCTs reviewed. Romjin et al. observed a
between group difference of -0.03(-4.1, 4.1) in DASS-42 scores (p ≥0.05). Chahwan et al.
observed an F score of 0.00 (p ≥0.05) for BDI-II scores, and an F score of 0.20 (p ≥0.05) for
DASS-21 scores. Akkasheh et al. found the change from baseline of BDI-I scores between the
placebo and probiotic group significant (p = 0.001), however this effect may have been
influenced by confounding variables.
Conclusions: Results from these three studies suggest the use of probiotics in decreasing
depressive symptoms in patients with low mood is not effective. More research is needed before
probiotics can be considered standard monotherapy, however its use as adjunctive treatment is
promising. Future studies should standardize the probiotics used and specify which severity of
depression or which symptom of depression probiotics are most effective at treating
Key Words: Depression, probiotics, Beck Depression Index, Depression Anxiety Stress Scale

TALT PROBIOTICS FOR DEPRESSIVE SYMPTOMS

1

Introduction
Depression can present itself in a variety of ways. Symptoms include sleep difficulties,
weight change, fatigue, feelings of guilt or worthlessness, lack of concentration, restlessness or
slowness, and recurrent thoughts of suicide.1 For an individual to be diagnosed with major
depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth
Edition (DSM-5) they must have five or more symptoms present within a two week period
almost every day for most days.1 One of these symptoms must also be either depressed mood or
anhedonia.1
About half of Americans will meet criteria for a DSM-5 disorder sometime in their life
beginning as early as childhood.2 However MDD has one of the highest lifetime prevalences at
20% and is a leading cause of disability for people aged 15-44 years in the United States.2,3 The
number of people being diagnosed with depression is also on the rise. Between 2010 and 2018,
the proportion of adults with MDD in the US aged 18-34 increased from 34.6% to 47.5%.4 This
jump helps explain the economic burden of adults with MDD in America in 2018 which was an
estimated $326.2 billion.4 Furthermore, the number of physician office visits with depressive
disorders as the primary diagnosis in 2018 was approximately 13 million.5
With such a high prevalence, it is important to examine the factors contributing to
depression. In addition to genetic and neurological causes, depressive symptoms can be linked to
disruptions in the gastrointestinal (GI) tract.6 The association is thought to involve the gut-brain
axis which is a bidirectional communication system between the GI tract and the central nervous
system involving the vagus nerve.7 Its function on the impact of mood and behaviors is still not
fully understood, however it was found to play a role in the integration of neural signals and
modulating psychological health.6 Patient with depression were found to have decreased gut
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barrier function which causes leakage of microbes across the epithelium and an increased release
of proinflammatory cytokines.6 This response leads to systemic inflammation that can affect the
conversion of tryptophan to serotonin; a neurotransmitter commonly low in depressive patients.6
As a result, changes in the gut microbiome are thought to contribute to depressive symptoms
which has changed how we think about treating the disorder.
Initial treatment for depression is psychotherapy, including cognitive behavioral therapy.
However increased efficacy is noted when combining psychotherapy with pharmacotherapy.
First line medication includes selective serotonin reuptake inhibitors (SSRIs) followed by
serotonin norepinephrine reuptake inhibitors (SNRIs), then tricyclic antidepressants (TCAs), and
lastly monoamine oxidase inhibitors (MAOIs). Some adjunctive medications to help with
additional symptoms include bupropion, trazadone, and mirtazapine. Finally, electroconvulsive
therapy can be used in patients resistant to medical therapy. While these treatments might be the
current standard of care, approximately one third of patients with depressive symptoms do not
respond to existing psychotherapy and pharmacological treatment.6 A significant number of
patients also refuse to seek treatment due to the associated stigma with depression.6
For this reason, efforts have been made to find another way to treat depression that is
non-invasive, more accessible to low-income patients, has limited side effects, and does not
come with the added stigma certain pharmacological medications may possess.8 The solution was
using probiotics to manipulate the gut microbiome to treat mood disorders.6 Probiotics are
defined by the Food and Agricultural Organization of the United Nations and World Health
Organization as live microorganisms that provide a beneficial health to the host when
administered in adequate amounts.9 When added to the gut microbiome, they decrease
proinflammatory cytokines like IL-6 and TNF-alpha which are increased in people with
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depression.6 This action helps decrease oxidative stress and is thought to mediate the decrease in
depressive symptoms via the gut-brain axis in a way that is not yet fully understood.6
Objective
The objective of this systematic review is to determine, “Do probiotics decrease
depressive symptoms in patients with low mood?”
Methods
The studies referenced in this review were found on PubMed using key words
“Depression”, “Probiotics”, and “NOT pregnancy”. All articles chosen were published in English
and in peer reviewed journals. Inclusion criteria consist of articles published after 2011 and
studies focusing on human subjects only. Exclusion criteria includes studies published before
2011, trials involving pregnancy or prebiotics, studies focusing on depression in conjunction
with other medical conditions, and studies focusing on a specific population. The demographics
and characteristics of these studies can be found in Table 1.
Studies used to answer the objective were chosen based on their attention to patientoriented evidence that matters (POEMS) and their relevance to the clinical question. Further
criteria used for selection included the population, interventions, comparisons, and outcomes
measured. All three studies were randomized, double blind, control trials that focused on patients
with low mood. All studies also required probiotics as the intervention and a probiotic placebo as
the comparison in measuring depressive symptoms as the outcome. Statistical analyses utilized
in these studies include p values, F-score, mean change from baseline, and between group
difference.
Outcomes Measured
All three articles utilized either the Beck Depression Index (BDI) and/or the Depression
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Table 1. Demographics and Characteristics of Included Studies
Study
Type
#
Age
Inclusion
Exclusion
Patients (yrs)
Criteria
Criteria
Romjin7 Double
79
≥16 Age ≥16yrs,
Neurological
2017
Blind
yrs DAAS-42 score renal,
RCT
≥14, QID-SR16 cardiovascular, or
score ≥11, off
respiratory
psychiatric
disease, medical
medication at
condition with
least 4weeks
intervention
prior to trial.
during trial,
pregnant,
breastfeeding,
taking
antidepressant
supplement,
suicidal, recent
probiotic use.
Chahwan6 Double
71
≥18 Age ≥18yrs
BDI ≥57,
2019
Blind
yrs BDI score ≥12, HIV/AIDS,
RCT
could provide
cancer/chemo,
informed
Crohn’s disease,
consent,
ulcerative colitis,
willing to
lactose or gluten
travel to testing intolerant,
site weekly,
suicidal or
could provide
homicidal
stool sample,
ideations,
not consuming alcoholic,
probiotics-rich pregnant,
foods,
currently taking
relatively
antidepressant,
healthy and not or consumed
on medication probiotics in the
for depression. last 2 weeks.
10
Akkasheh Double
40
20-55 MDD DSM-5
Age <20 or >55,
2016
Blind
yrs diagnosis,
history of
RCT
score ≥15 on
coronary
17 item
infarction,
Hamilton
angina pectoris,
Depression
pregnancy,
Rating Scale.
lactation, or
substance abuse;
or taking
probiotics in the
last 2 months

W/ Interventions
D
10 Sachet
containing
probiotic and
excipients
dispensed orally
once daily for 8
weeks versus a
visually identical
placebo sachet
containing just
the excipients
(xylitol,
maltodextrin,
plum flavor, and
malic acid.
33 Sachet
containing
freeze-dried
probiotic powder
mixture, maizestarch and
maltodextrins
dispensed twice
daily for 8 weeks
versus the
visually identical
placebo
containing just
the freeze dried
maize-starch and
maltodextrins
5

Probiotic
capsule taken
once daily
versus visually
identical
placebo capsule
containing
starch for 8
weeks.
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Anxiety Stress Scale (DASS) to measure the severity of depressive symptoms. BDI-I was
utilized by Akkasheh et al.10, and BDI-II was used by Chahwan et al.6 Both versions are a selfreported 21 item questionnaire where individuals choose which depressive statement out of four
they relate to the most for each item.10 The different statements focus on POEMs including sleep,
appetite, decision making abilities, feelings of guilt, etc.11 The least depressive statement is given
a score of 0 and the most depressive is scored a 3. The total BDI is calculated by adding together
the scores of each item.9 The higher the score, the more severe the level of depression. BDI-I
ranges from 0 to >40, while BDI-II ranges from 0 to 63.10,11
The DASS is a self-report questionnaire that assesses the severity of symptoms relating to
depression, anxiety, and stress.12 For this paper, only the scores related to depression were
considered. Chahwan et al.6 utilized the 21-item DASS while Romijn et al.7 utilized the 42-item
DASS. Individuals are asked how much a POEM-related statement applied to them over the past
week by rating it on a 4 point scale.12 A score of 0 indicates “Did not apply to me at all” while 3
indicates “Applied to me very much or most of the time”.12 Scores for depression are calculated
by totaling the ratings from depressive relevant items only. As with the BDI, the higher the
DASS score the more severe the depression. Scores ranged from 0 to >28.12 In this selective
EBM, the outcome measured is the decrease in depressive symptoms based on BDI and DASS
scores before and after intervention.
Results
All three studies in this review were double blind RCTs that excluded participants
recently taking probiotics and those with chronic medical conditions needing medical
intervention during the trials as seen in Table 1. Akkasheh et al.10 is the only study that did not
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exclude patient recently taking antidepressants but did restrict participants from taking
medications during the trial that could affect findings. Romijn et al.7 recruited individuals ≥16
years old who had not been on psychiatric medication at least 4 weeks prior to the trial. The
participants also required to have at least moderate depressive symptoms as indicated by a Quick
Inventory of Depressive Symptomatology (QIDS-SR16) score ≥11 and a DASS-42 score ≥14.12
The participants were then randomized in blocks of 10 into either the probiotic or placebo group
at a 1:1 ratio using www.randomization.com.7 Out of the 79 individuals randomized, 40 were
allocated to the probiotic group and 39 to the placebo group.7 DASS-42 scores were recorded at
baseline and at the end of the 8-week trial.7 Once daily the probiotic group orally ingested a
sachet containing probiotic and excipients while the placebo group orally ingested an identical
placebo sachet containing just the excipients (xylitol, maltodextrin, plum flavor, and malic
acid).7 Significant adverse effects were mostly observed in the placebo group and included dry
mouth, sleep disturbances, and suicide attempts.7 There were no serious adverse events in the
probiotic group as the suicide attempts were only from one participant in the placebo group.7 By
the end of the 8-week trial, 10 participants were withdrawn from the study due to antibiotic use,
antidepressant use, or because they dropped out.7 However, all patients were analyzed in the
groups to which they were randomized on an intention-to-treat-basis.7
After the trial, the change in baseline of DASS-42 scores for both the probiotic and
placebo group were calculated using mean values from before and after treatment.7 As seen in
Table 2, the probiotic group had a mean DASS-42 score of 24.2±9.1 at baseline and a mean of
13.2±11.6 at week 8 making the change from baseline -9.9.7 The placebo group had a mean
DASS-42 score of 19.±10.5 at baseline and a mean of 10.3±8.8 at week 8 making the change
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from baseline -9.9.7 Using more accurate values not provided, the between group difference was
then calculated as -0.03(-4.1, 4.1) with a p-value of 0.99 which was not significant (p≥0.05).7
Table 2. Changes in DASS-42 scores from Baseline to Week 8 in Romijn et al.
Group
Baseline
Week 8
Mean Change Difference between
(Mean ± SD) (Mean ± SD) from Baseline Groups (95% CI)
Probiotic 24.2±9.1
13.2±11.6
-9.9
-0.03 (-4.1, 4.1)
Placebo 19.±10.5
10.3±8.8
-9.9

p-value
0.99

Chahwan et al.6 enrolled participants who were age ≥18yrs, not currently taking
antidepressants, and scored between 12 and 57 on the BDI-II indicating minimal and moderate
depressive symptoms, but not severe.11 This criteria ensured participants were not actively
suicidal or self-harming.6 Out of the 71 participants enrolled, 34 were allocated to the probiotic
group and 37 to the placebo group.6 Allocation was performed randomly by a computerized
randomizer in blocks of four.6 BDI-II and DASS-21 scores were recorded at baseline and after
the 8-week trial.6 Stool samples were also collected for analysis of additional values not
discussed in this paper.6 Twice daily the probiotic group orally consumed a sachet containing
freeze-dried probiotic powder mixture, maize-starch, and maltodextrins while the placebo group
orally consumed a visually identical placebo mixture containing just the freeze dried maizestarch and maltodextrins.6 Adverse effects included nausea, dry mouth, drowsiness, and
dehydration. These effects were mild, temporary, and did not interfere with the participant’s
ability to complete the trial.6 At the end of the 8-week trial, 33 participants were withdrawn from
the study due to failure to provide stool sample, commencement of medication/treatment,
inability to travel, loss to follow-up, or no reason given.6 All patients were analyzed in the
groups to which they were randomized on an intention-to-treat-basis.6
After the trial, the mean BDI-II and DASS-21 scores were calculated at baseline and at
week 8 as seen in Table 3. The probiotic group experienced a decline in BDI-II scores from
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28.91±10.10 to 19.88±13.44 compared to the placebo group which declined from 27.97±9.79 to
19.25±11.96.6 Using this data an F score of 0.00 was calculated to compare the between group
difference and the difference before and after intervention within each group. This value was not
significant as shown by a p-value of 0.98 (p≥0.05) 6. For the DASS-21 scores, the probiotic
group decreased from 22.88±9.96 at baseline to 15.18±11.03 at week 8 while the placebo group
decreased from 20.43±10.76 at baseline to 12.97±9.34 at week 8.6 From these values an F score
of 0.20 was calculated with a p-value of 0.65 which was also not significant (p≥0.05).6
Table 3. Changes in BDI-II and DASS-21 scores from Baseline to Week 8 in Chahwan et al.
Index/Scale Group
Baseline (Mean ± SD) Week 8 (Mean ± SD) F Statistic p-value
Probiotic
28.91±10.10
19.88±13.44
BDI-II
0.00
0.98
Placebo
27.97±9.97
19.25±11.96
Probiotic
22.88±9.96
15.18±11.03
DASS-21
0.20
0.36
Placebo
20.43±1076
12.97±9.34
Akkasheh et al.10 enrolled participants between the ages of 20 and 55 years old and with a
diagnosis of MDD based on the DSM-5 criteria. Participants were also required to score ≥15 on
the 17 item Hamilton Depression Rating Scale which indicates mild to moderate depression.13
Out of the 40 participants deemed eligible, 20 were allocated to the probiotic group and 20 to the
placebo group.10 Allocation was performed randomly using a computer-generated random
numbers.10 BDI-I scores were recorded at baseline and at the end of the 8-week trial.10 Once
daily the probiotic group orally consumed a capsule containing three species of probiotics while
the placebo group consumed an identical capsule that contained starch and no bacteria.10 Adverse
events were not indicated.10 At the end of the 8 week trial, 5 participants were discontinued from
the study after withdrawing due to personal reasons.10 However, all patients were analyzed in the
groups to which they were randomized on an intention-to-treat-basis and missing values were
analyzed using the last-observation-carried-forward-method.10
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After the trial, BDI-I scores were calculated by totaling all the scores at baseline and at
week 8.10 The change in mean from baseline of total BDI-I scores for the probiotic group was 5.7±6.4 compared to the placebo group which was -1.5±4.8 as seen in Table 4. Using a paired
sample t-test (data not provided), the decrease from baseline of the probiotic group compared to
the placebo group was determined significant by a p value of 0.001 (p<0.05).10 However, this
value may have been influenced by recent use of antidepressants in participants before the trial
and the significant difference in fasting blood glucose (FBG) levels between the groups at
baseline.10 After adjusting for the FBG, the p value was 0.05 and not significant (p≥0.05).10
Table 4. Mean Change from Baseline of BDI-I scores in Akkasheh et al.
Group
Mean Change from Baseline (Mean ± SD) p-value
Probiotic
-5.7±6.4
0.001
Placebo
-1.5±4.8
Discussion
Depression is a prevalent mental health disorder that can negatively affect an individual’s
quality of life if not treated. Symptoms range from weight changes, to decreased cognition, and
even suicidal ideations.1 As a result, finding an effective treatment option patients are willing to
try has been investigated in the form of probiotics. This treatment is non-invasive, has limited
side effects, can be more accessible to low-income patients, and does not come with the added
stigma certain pharmacological medications may possess.8
This review evaluated the efficacy of probiotics on decreasing depressive symptoms in
patients with low mood by examining three RCTs. Romijn et al.7 and Chahwan et al.6 found the
decrease in depressive symptoms among the probiotic group compared to the placebo group not
significant (p≥0.05), while Akkasheh et al.10 did (p<0.05). Before accepting these results, some
concerns with validity should be discussed. After adjusting for the difference in FBG levels at
baseline, results were no longer significant in Akkasheh et al. (p≥0.05).10 It is also unclear
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whether recent pharmacotherapy use influenced outcomes since previous antidepressant use
among participants was not recorded. Antidepressants consumed the day prior to the trial could
have interfered with results since effects can last hours to days after discontinuation.14
All three RCTs also tested the effects of probiotics over an 8-week trial which may not
have been long enough to observe its effects on mood. Patients are currently recommended to
give antidepressants like SSRIs a trial of 4-6 weeks before observing therapeutic effects.8
Therefore, it is recommended more long term studies be performed. Additionally, it is
recommended that future studies be more consistent in the type and frequency of probiotics
administered to standardize results. The RCTs examined all used different combinations of
probiotics and had them administered either once or twice daily. It is recommended that future
trials use Lactobacilus casei since it is the most frequently used probiotic strain in similar
studies.8 Other limitations observed include limited generalizability due to small sample sizes
and single site studies, specifically noted in Chahwan with an attrition rate of 34%.6
Therefore, while these three RCTs do not support the effectiveness of probiotics as
standard monotherapy for depressive symptoms, its use as adjunctive treatment should be
investigated. Combination treatment of probiotics and pharmacotherapy should be examined
similarly to combined psychotherapy and pharmacotherapy. Akkasheh et al. is the only study
that did not exclude patient who recently took antidepressants and was also the only study with
significant results. While it is uncertain whether this variable is the reason for the significant
outcome, it does support findings by Logan and Katzman15 who suggest probiotics can be
beneficial as adjunctive therapy to standard MDD care due to its added benefit on gut microflora.
Although Romijn et al.7 and Chahwan et al.6 did not produce significant results as seen in
Table 2 and Table 3, it is important to note both observed a drop in depressive symptom severity
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among both groups over the course of the trial. This result suggests performing actions aimed at
improving their symptoms alone could have positively impacted participant’s mood outside of
probiotic use.6 A meta-analysis supports this idea by indicating activity scheduling is an effective
depressive treatment in adults, and in some cases just as effective as cognitive therapy.16
Additionally, probiotic use may only be beneficial at certain severities of depression or at
improving specific depressive symptoms. While Chahwan et al. did not observe a significant
difference in depressive symptoms, the study found positive effects of probiotics on cognitive
reactivity towards sad moods.6 After intervention, there were lower cognitive reactivity scores in
participants with mild/moderate depressive symptoms over those with severe depressive
symptoms.6 This result, also proposed by Romijn et al, suggest probiotics are more
effective in patients with less severe depression.7 It also may suggest probiotics are specifically
more beneficial at improving cognitive process compared to other depressive symptoms.
Conclusion
According to the results in this systemic review, the use of probiotics in decreasing
depressive symptoms in patients with low mood is not effective. Only Akkasheh et al. found the
decrease in depressive symptoms between the placebo and probiotic group significant, however
this effect may have been influenced by confounding variables.10 Results from both Romijn and
Chahwan were not significant, but support activity scheduling as a treatment for depression.6,7
Future studies should also standardize the probiotics used and specify which severity of
depression or which symptom of depression probiotics are most effective at treating. While this
selective EBM does not support the use of probiotics as first line monotherapy for depressive
symptoms, the use of probiotics as adjunctive treatment should be further investigated.
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